Tuesday, October 13, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 13, 2026

Citigroup Trades at a Discount to Industry: How to Play the Stock?

View original at finance.yahoo.com
Citigroup Trades at a Discount to Industry: How to Play the Stock? Citigroup, Inc. C stock is currently trading at a 12-month trailing price-to-earnings (P/E) of 10.67X, which is below the industry’s 14.42X…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Revenues expected to see 4-5% CAGR through 2026

    80% confidence

  • Prudent stance is holding Citigroup stock - risks temper bullish case despite improving fundamentals

    80% confidence

  • Expects to achieve $2-2.5 billion in annualized run rate savings by 2026

    80% confidence

  • Target return on tangible common equity (RoTCE) of 10-11% in 2026

    80% confidence

  • Citigroup stock trading at P/E of 10.67X below industry average of 14.42X

    80% confidence

  • 2026 earnings expected to rally 28.2% year-over-year, 2027 earnings expected to rally 17.8%

    80% confidence

  • NII excluding markets expected to increase 5-6% year over year in 2026

    80% confidence

  • Plans to increase Japan investment banking headcount by 30% by first half of 2026

    80% confidence

Data points we hold from this source

Citigroup Inc. · debt335.8 billion_USD
Citigroup Inc. · cash and investments476.7 billion_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com
Citigroup Trades at a Discount to Industry: How to Play the Stock? — Source | Via News | Via News